AJP - Heart Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (January 4, 2008). doi:10.1152/ajpheart.00174.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/3/H1274    most recent
00174.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yan, X.
Right arrow Articles by Morgan, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yan, X.
Right arrow Articles by Morgan, J. P.
Submitted on February 16, 2006
Accepted on December 14, 2007

Pressure Overload-induced Hypertrophy in Transgenic Mice Selectively Overexpressing AT2 Receptors in Ventricular Myocytes

Xinhua Yan1, Adam JT Schuldt2, Robert L Price3, Ivo Amende4, Fen-Fen Liu2, Katashi Okoshi2, Kalon KL Ho2, Adele J Pope5, Thomas K Borg3, Beverly H Lorell2, and James P. Morgan4*

1 Medicine, Cardiovascular Medicine, Caritas St. Elizabeth's Medical Center, Brighton, Massachusetts, United States
2 Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
3 Developmental biology and anatomy, University of South Carolina, Columbia, South Carolina, United States
4 Medicine, Caritas St. Elizabeth's Medical Center, Brighton, Massachusetts, United States
5 Developmental Biology and Anatomy, University of South Carolina, Columbia, South Carolina, United States

* To whom correspondence should be addressed. E-mail: james.morgan{at}caritaschristi.org.

Background: The role of the Angiotensin II type 2 receptor (AT2) in cardiac hypertrophy remains controversial. Here we studied the effects of AT2 on chronic pressure overload-induced cardiac hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes. Methods: Left ventricular hypertrophy was induced by banding of the ascending aorta (AS). Transgenic mice overexpressing AT2 (AT2TG-AS) and non-transgenic mice (NTG-AS) were studied after 70 days of aortic banding. Non-banded NTG mice were used as controls. Left ventricular (LV) function was determined by catheterization via LV puncture and cardiac magnetic resonance imaging. LV myocyte diameter and interstitial collagen were determined by confocal microscopy. ANP and BNP were analyzed by Northern blot. SERCA2, iNOS, eNOS, ERK1/2, P70S6K, SHP-1 and PP2A were analyzed by Western blot. Results: LV myocyte diameter and collagen were significantly reduced in AT2TG-AS compared to NTG-AS mice. LV anterior and posterior wall thickness were not different between AT2TG-AS and NTG-AS mice. LV systolic and diastolic dimensions were significantly higher in AT2TG-AS than in NTG-AS mice. LV systolic pressure and LV end-diastolic pressure were lower in AT2TG-AS than in NTG-AS mice. ANP and BNP were not different between AT2TG-AS and NTG-AS mice. SERCA2 was not different between AT2TG-AS and NTG-AS mice. PLB and the PLB/ SERCA2 ratio were significantly higher in AT2TG-AS than in NTG-AS mice. iNOS was higher in AT2TG-AS than in NTG-AS mice but not significantly different. Conclusion: Our results indicate that AT2 receptor overexpression modified the pathological hypertrophic response to aortic banding in transgenic mice.




This article has been cited by other articles:


Home page
CirculationHome page
P. Verdecchia, P. Sleight, G. Mancia, R. Fagard, B. Trimarco, R. E. Schmieder, J.-H. Kim, G. Jennings, P. Jansky, J.-H. Chen, et al.
Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease
Circulation, October 6, 2009; 120(14): 1380 - 1389.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.